In contrast, during AML maintenance, we functionally demonstrate that WT Ezh2 plays an oncogenic role and show that it can be effectively therapeutically targeted to up-regulate an entirely different and tumor-suppressive program. Here, EZH2 is linked to acute myeloid leukemia.